Advertisement
U.S. markets close in 2 hours 47 minutes

Ikena Oncology, Inc. (IKNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
1.3200-0.0300 (-2.22%)
As of 01:05PM EDT. Market open.
Full screen
Add
Comparison
Indicators
Technicals
Corporate Events
Mountain
DrawTable View
Settings
AllAllFavoritesTextStatisticsTechnicalsFibonacciMarkingsLines
Loading interactive chart...
1D
Date Range
Interval:
1 min
  • GlobeNewswire

    Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

    BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. Details are as follows: Date: Tuesday, April 16, 2024Time: 2:00 p.m. ETWebcast

  • Simply Wall St.

    Ikena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

    Ikena Oncology ( NASDAQ:IKNA ) Full Year 2023 Results Key Financial Results Net loss: US$68.2m (flat on FY 2022...

  • GlobeNewswire

    Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

    IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”)